Pliant Therapeutics, Inc. PLRX
0.79 USD -0.01 (-1.74%)
At closeNov 11, 2026, 8:37 AM EST
0.79 0.00 -0.09%
Pre-market · Nov 11, 8:37 AM ET
0.77 Day range 0.8187
0.77 52-week range 1.82
- YTD
- -35.60%
- 1 year
- -51.50%
News
globenewswire.com Pliant Therapeutics Announces Presentation of PLN-101095 Preclinical and Clinical Data at the 2026 Annual Meeting of the Society for Immunotherapy of Cancer SOUTH SAN FRANCISCO, Calif., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), today announced the presentation of preclinical proof-of-concept data and new clinical…
benzinga.com Pliant Therapeutics Receives Fast Track Designation From FDA For PLN-101095 In Combination With Pembrolizumab For Potential Treatment Of Solid Tumors Pliant Therapeutics, Inc. (NASDAQ:PLRX) today announced the receipt of Fast Track designation from the U.S. Food and Drug Administration (FDA) for PLN-101095, an oral, small molecule, dual selective…
benzinga.com Pliant Therapeutics Q2 EPS $(0.36) Misses $(0.34) Estimate Pliant Therapeutics (NASDAQ:PLRX) reported quarterly losses of $(0.36) per share which missed the analyst consensus estimate of $(0.34) by 5.88 percent. This is a 49.3 percent increase over losses of…
benzinga.com Pliant Therapeutics Announces Dosing Of First Participant In FORTIFY Phase 1b Open-Label Indication Expansion Clinical Trial Of PLN-101095 In Combination With Pembrolizumab, In Patients With ICI-Refractory Advanced Or Metastatic Solid Tumors Pliant Therapeutics (NASDAQ:PLRX) today announced the dosing of the first participant in the FORTIFY Phase 1b open-label indication expansion clinical trial of PLN-101095 in combination with…- benzinga.com Pliant Therapeutics Presents Data From Phase 1 Trial Of PLN-101095 At AACR Annual Meeting 2026 Pliant Therapeutics, Inc. (NASDAQ:PLRX), a clinical-stage biotechnology company focused on the discovery and development of integrin-based therapeutics, today announced the presentation of data from…
- benzinga.com Canaccord Genuity Maintains Hold on Pliant Therapeutics, Lowers Price Target to $3 Canaccord Genuity analyst Edward Nash maintains Pliant Therapeutics (NASDAQ:PLRX) with a Hold and lowers the price target from $4 to $3.
benzinga.com Piper Sandler Maintains Overweight on Pliant Therapeutics, Lowers Price Target to $3 Piper Sandler analyst Yasmeen Rahimi maintains Pliant Therapeutics (NASDAQ:PLRX) with a Overweight and lowers the price target from $4 to $3.
benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session - benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session 
benzinga.com Tesla, ON Semiconductor And Other Big Stocks Moving Lower In Monday's Pre-Market Session 
benzinga.com Why BP Shares Are Trading Higher By 6%; Here Are 20 Stocks Moving Premarket - benzinga.com Why RH Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket
benzinga.com Fisker, Intercept Pharmaceuticals, Immunovant And Other Big Stocks Moving Higher On Tuesday U.S. stocks traded lower, with the Dow Jones falling around 200 points on Tuesday. Here are some big stocks recording gains in today’s session.
benzinga.com Stocks That Hit 52-Week Lows On Thursday During the session on Thursday, 461 stocks hit new 52-week lows.- benzinga.com Stocks That Hit 52-Week Lows On Friday Friday's session saw 169 companies set new 52-week lows.
benzinga.com Benzinga's Top Ratings Upgrades, Downgrades For December 14, 2022 - benzinga.com Why Stabilis Solutions Shares Jumped Over 71%; Here Are 70 Biggest Movers From Yesterday Gainers
benzinga.com Why Adamis Pharmaceuticals Is Trading Lower By Around 44%, Here Are 46 Stocks Moving In Wednesday's Mid-Day Session Gainers- benzinga.com Alibaba, Zoom Video And 76 Biggest Movers From Yesterday Gainers Kaspien Holdings Inc. (NASDAQ: KSPN) shares climbed 161.9% to close at $6.81 on Monday on heavy volume amid mention of the stock on social media.
- benzinga.com Why These Casino Stocks Are Moving Lower, Here's 45 Stocks Moving In Monday's Mid-Day Session Gainers Pliant Therapeutics, Inc. (NASDAQ: PLRX) jumped 112.6% to $18.88 after the company said its treatment for Idiopathic Pulmonary Fibrosis was well tolerated in a Phase 2a study.
- benzinga.com Stocks That Hit 52-Week Lows On Wednesday On Wednesday, 807 companies reached new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Thursday During Thursday, 849 stocks hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Tuesday On Tuesday, 242 companies hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Tuesday During Tuesday's session, 454 stocks hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Monday On Monday, 671 companies achieved new lows for the year.
- benzinga.com Stocks That Hit 52-Week Lows On Tuesday During Tuesday's trading, 505 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Friday On Friday, 313 companies hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Friday On Friday morning, 155 companies achieved new lows for the year.
benzinga.com 63 Biggest Movers From Yesterday Gainers- benzinga.com 41 Stocks Moving In Friday's Mid-Day Session Gainers
- benzinga.com Benzinga's Top Ratings Upgrades, Downgrades For April 20, 2021
- benzinga.com Stocks That Hit 52-Week Highs On Thursday Before 10 a.m. ET Thursday, 371 stocks hit new 52-week highs.
- benzinga.com Stocks That Hit 52-Week Highs On Monday During Monday's morning trading, 285 companies set new 52-week highs.
- benzinga.com Stocks That Hit 52-Week Lows On Friday Before 10 a.m. ET on Friday, 30 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Thursday Before 10 a.m. ET Thursday, 132 stocks made new 52-week lows.